ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "risk assessment"

  • Abstract Number: 0563 • ACR Convergence 2021

    Validating the FRAX Score in a US Population-Based Study of Patients with Rheumatoid Arthritis

    Madeline Peterson1, Cynthia Crowson2, Elena Myasoedova1, Shreyasee Amin1, John Davis1, Sara Achenbach1, Sundeep Kholsa1 and Elizabeth Atkinson1, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Eyota, MN

    Background/Purpose: The FRAX tool, launched by the World Health Organization Collaborating Centre at the University of Sheffield in 2008 (https://www.sheffield.ac.uk/FRAX/), is widely used to quickly…
  • Abstract Number: 0645 • ACR Convergence 2021

    Time Burden of QTc Screening for HCQ Users at a Single VA Rheumatology Clinic

    Iziegbe Ehiorobo1, Anna Montgomery2 and Gabriela Schmajuk1, 1University of California San Francisco, San Francisco, CA, 2Department of Veterans Affairs, Tiburon, CA

    Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used medication in the treatment of rheumatic diseases. New guidance from the ACR supports routine monitoring of the QT…
  • Abstract Number: 0648 • ACR Convergence 2021

    Improving Post-Rituximab Hypogammaglobulinemia Risk Assessments: A Fellows’ Quality Improvement Initiative

    Beth Rutstein1, Melissa Argraves2, Atiye Bilgic Dagci2, Sarah Bayefsky2, Julia Rood2, Julie Chase3, Jay Mehta2, Melissa Lerman2, Cory Stingl4 and Jon Burnham2, 1Children's Hospital of Philadelphia, Wynnewood, PA, 2Children's Hospital of Philadelphia, Philadelphia, PA, 3The Children's Hospital of Philadelphia, Philadelphia, PA, 4Children's Hospital of Philadelphia, Durham, NC

    Background/Purpose: Hypogammaglobulinemia following rituximab therapy is a potentially severe complication that can lead to infection-related morbidity and mortality. If recognized, clinicians may prevent infections by…
  • Abstract Number: 1054 • ACR Convergence 2021

    Metabolomics as an Innovative Tool for Cardiac Risk Stratification in Patients with Rheumatic Diseases: Results from a Pilot Study

    Sorwe Mojtahed Poor1, Lisa Hahnefeld2, Frank Behrens3, Harald Burkhardt4, Michaela Köhm5, Geisslinger Gerd6 and Gurke Robert7, 1University hospital Frankfurt Devision Rheumatology and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt am Main, Germany, 2pharmazentrum frankfurt/ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt/Main, Germany, Frankfurt, Germany, 3Rheumatology & Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Fraunhofer Cluster Immune-Mediated Diseases (CIMD), Fraunhofer Cluster Immune-Mediated Diseases (CIMD), Frankfurt/Main, Germany, 4University hospital Frankfurt Devision Rheumatology and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, 5University hospital Frankfurt Devision Rheumatology and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, 6Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, 7pharmazentrum frankfurt/ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany

    Background/Purpose: Patients with rheumatic diseases (RMD) face an increased cardiovascular (CV) mortality compared to the general population. Still, risk stratification based on traditional cardiovascular risk…
  • Abstract Number: 1328 • ACR Convergence 2020

    Cardiac Biomarkers Are Associated with the Development of Cardiovascular Events in Patients with Psoriatic Arthritis and Psoriasis

    Keith Colaco1, Ker-Ai Lee2, Shadi Akhtari3, Raz Winer4, Paul Welsh5, Naveed Sattar5, Iain McInnes6, Vinod Chandran7, Paula Harvey8, Richard Cook2, Dafna Gladman7, Vincent Piguet8 and Lihi Eder9, 1Institute of Medical Science, University of Toronto; Women's College Research Institute, Women's College Hospital; and Toronto Western Hospital, University Health Network, Toronto, ON, Canada, 2University of Waterloo, Waterloo, ON, Canada, 3Women's College Hospital, University of Toronto, North York, ON, Canada, 4Rambam Health Care Campus, Haifa, Israel, 5University of Glasgow, Glasgow, Scotland, United Kingdom, 6Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, 7Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 8Women's College Hospital, University of Toronto, Toronto, ON, Canada, 9Women’s College Research Institute, University of Toronto, Toronto, ON, Canada

    Background/Purpose: N-terminal pro-brain-type natriuretic peptide (NT-proBNP) and troponin I (TnI) are established cardiac biomarkers that predict cardiovascular events (CVEs) and mortality in apparently healthy individuals…
  • Abstract Number: 1475 • ACR Convergence 2020

    Predictors of Thirty-Day Hospital Readmissions in Systemic Lupus Erythematosus in the US: A Nationwide Study

    Rayan Najjar1, Swetha Ann Alexander2, Grant Hughes1, Jinoos Yazdany3 and Namrata Singh4, 1University of Washington, Seattle, WA, 2University of Connecticut, Hartford, CT, 3UCSF, San Francisco, CA, 4University of Washington, Bellevue, WA

    Background/Purpose: For individuals with systemic lupus erythematosus (SLE), hospital readmission rate is associated with quality of care and prognosis. Our objective was to evaluate independent…
  • Abstract Number: 0181 • ACR Convergence 2020

    Methotrexate Use Does Not Increase the Prevalence of Hepatic Steatosis: A Real-World Retrospective Nested Case-Control Study

    Yunjung Choi1, Chang-Hun Lee1, Myeung-Su Lee2, Chang-Hoon Lee2, SoJeong Park3 and Wan-Hee Yoo4, 1Jeonbuk National University Hospital, Jeonju, Republic of Korea, 2Wonkwang University Hospital, Iksan, Republic of Korea, 3Data Science Team, Hanmi Pharm. Co., Ltd, Seoul, Romania, 4Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, Jeonju, Republic of Korea

    Background/Purpose: We aimed to determine whether methotrexate (MTX) treatment in patients with rheumatoid arthritis (RA) leads to the development of nonalcoholic fatty liver (NAFL).Methods: Data…
  • Abstract Number: 1576 • ACR Convergence 2020

    Acute Respiratory Viral Adverse Events During Use of Antirheumatic Disease Therapies: A Scoping Review

    Adam Kilian1, Yu Pei Eugenia Chock2, Irvin Huang3, Elizabeth Graef4, Laura Upton5, Aneka Khilnani6, Sonia Silinsky Krupnikova7, Ibrahim Almaghlouth8, Laura Cappelli9, Ruth Fernandez-Ruiz10, Brittany Frankel3, Jourdan Frankovich11, Carly Harrison12, Bharat Kumar13, Kanika Monga14, Jorge Rosario Vega11, Namrata Singh15, Jeffrey Sparks16, Elaine Sullo6, Kristen Young17, Ali Duarte-Garcia18, Michael Putman19, Sindhu Johnson20, Jean Liew3 and Aruni Jayatilleke21, 1George Washington University, Washington, DC, 2Yale School of Medicine, Greenwich, CT, 3University of Washington, Seattle, WA, 4Beth Israel Deaconess Medical Center, Boston, MA, 5Georgetown University School of Medicine, Washington, DC, 6The George Washington University School of Medicine and Health Sciences, Washington, DC, 7The George Washington University School of Medicine and Health Sciences, Rockville, MD, 8King Saud University, Riyadh, Saudi Arabia, 9Johns Hopkins School of Medicine, Baltimore, MD, 10New York University School of Medicine, New York, 11Temple University, Philadelphia, PA, 12Lupus Chat, NA, 13University of Iowa Hospitals and Clinics, Iowa City, IA, 14UT Health Rheumatology, HOUSTON, TX, 15University of Washington, Bellevue, WA, 16Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 17University of Texas Southwestern Medical Center, Dallas, TX, 18Mayo Clinic, Rochester, MN, 19Northwestern University, Chicago, IL, 20University of Toronto, Toronto, ON, Canada, 21Section of Rheumatology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA

    Background/Purpose: COVID-19 threatens the health of people worldwide, although it remains unclear to what extent antirheumatic disease therapies increase susceptibility to complications of viral respiratory…
  • Abstract Number: 0225 • ACR Convergence 2020

    Prevalence and Probability Assessment of Adverse Drug Reactions in Rheumatoid Arthritis Patients Receiving Intravenous Originator Biologics in Saudi Arabia: A Longitudinal Five Years Follow-up Study

    Hawazin Alhazzani1, Reem Tashkandi1, Lamia Alzamel1, Haya Almalag1, Shiekha Alaujan1, Abdurhman Alarfaj1, Hussain Alarfaj1 and Mohammed Omair1, 1King Saud University, Riyadh, Saudi Arabia

    Background/Purpose: Biologics have been advocated by guidelines as effective therapies for rheumatoid arthritis (RA)1. Limited longitudinal studies investigated the prevalence and risk factors for developing…
  • Abstract Number: 1579 • ACR Convergence 2020

    Assessing the Effect of Calcineurin Inhibitors for Immune-related Adverse Event Management on Tumor Response

    Pankti Reid1, Daniel Olson2 and Thomas Gajewski2, 1University of Chicago, Chicago, IL, 2University of Chicago Medical Center, Department of Medicine, Section of Hematology Oncology, Chicago

    Background/Purpose: High grade immune-related adverse events (irAEs) to cancer immune checkpoint inhibitors (ICI) require considerable immunosuppression (IS) with high-dose steroids and steroid-sparing IS (SSIS) for…
  • Abstract Number: 0244 • ACR Convergence 2020

    What Are the Early versus Late Predictors for Systemic Lupus Erythematosus (SLE) Diagnosis?

    Yiting Wang1, Kirsten Lum2, Karen Costenbader3, Grace Wang4, Jennifer Lofland5, Dominik Naessens6, Yihan Zhao7, Kourtney Davis8 and Chetan Karyekar9, 1Janssen Research & Development, LLC, Newark, DE, 2Janssen Pharm Technology - Data Sciences and Data Management, Horsham, PA, 3Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 4Janssen Pharmaceuticals, Horsham, 5Janssen Global Market Access, horsham, PA, 6Jassen Global Market Access, Beerse, Belgium, 7Janssen Pharm Technology - Data Sciences and Data Management, Horsham, 8Janssen R&D, LLC, Titusville, NJ, 9Janssen Global Services, LLC, Horsham, PA

    Background/Purpose: SLE is clinically heterogenous and its diagnosis is often difficult or delayed. The length of time from symptom onset or from when patients seek…
  • Abstract Number: 1722 • ACR Convergence 2020

    Predicting Rheumatoid Arthritis Using the Symptoms in Persons at Risk of Rheumatoid Arthritis (SPARRA) Questionnaire

    Laurette van Boheemen1, Marieke ter Wee2, Marie Falahee3, Marian van Beers4, Axel Finckh5, Aase Hensvold6, Karim Raza7 and Dirkjan van Schaardenburg8, 1Amsterdam Rheumatology and immunology Center | Reade, Amste, Netherlands, 2Amsterdam Rheumatology and Immunology Center, location Amsterdam UMC, VUmc, Amsterdam, Netherlands, 3Sandwell and West Birmingham Hospitals NHS Trust, Birminham, United Kingdom, 4Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, 5Division of Rheumatology, University Hospitals of Geneva, Geneva, Switzerland, 6Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, 7Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom, 8Amsterdam Rheumatology and immunology Center | Reade and Amsterdam UMC, Amsterdam, Netherlands

    Background/Purpose: Accurate prediction of rheumatoid arthritis (RA) development in persons at risk can help to select individuals for early intervention trials. At-risk individuals exhibit a…
  • Abstract Number: 0558 • ACR Convergence 2020

    Statin Use Pattern in Patients with Inflammatory Joint Disease in a Single Site VA Medical Center

    Lenche Kostadinova1, Sofi Damjanovska2, Angela Gupta3, Ibtissam Gad4, Sameena Syed4, Alyssa Lange5, Corinne Kowal6, Carey Shive7, Christopher Burant4, Brigid Wilson4, David Canaday4, David Zidar8, Donald Anthony9 and Maya Mattar10, 1(1) Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Highland Heights, OH, 2(1) Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, OH, 3(1) Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, 4(1) Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, ohio, 5Case Western Reserve University, Cleveland, 6Case western reserve university/Cleveland VA Medical Center, ohio, 7(2) Department of Pathology, Case Western Reserve University, ohio, 8Case Western Reserve University/Cleveland VA Medical Center, Cleveland, 9Case Western Reserve University/Cleveland VA Medical Center/MetroHealth Medical Center, Cleveland, OH, 10Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, OH

    Background/Purpose: Patients with inflammatory joint disease, including rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) carry increased risk of cardiovascular disease (CVD). Mechanisms…
  • Abstract Number: 1751 • ACR Convergence 2020

    Forecasting Healthcare Utilization in Rheumatoid Arthritis: A Machine Learning Predictive Model of Emergency Department Visits and Prednisone Initiation in a Single Tertiary Academic Center

    Elston He1, Eli Cornblath2, Pratyusha Yalamanchi3, Alexis Ogdie2, Joshua Baker2 and Michael George2, 1Synovium, Inc., Philadelphia, PA, 2University of Pennsylvania, Philadelphia, PA, 3Michigan Medicine, Ann Arbor, MI

    Background/Purpose: Despite recent advances in therapy, 42% of patients with rheumatoid arthritis (RA) nationwide had moderate or high disease activity at their most recent visit.…
  • Abstract Number: 0730 • ACR Convergence 2020

    To Taper or Not to Taper in Juvenile Idiopathic Arthritis: Is There a Risk of Development of Uveitis Flares?

    Maria Teran1, Alina Lucica Boteanu2, Carlos Guillen1, Cristina Pijoan1, Jose Quinones1, Veronica Garcia3, Ivan Del Bosque-Granero3, Laura Calvo-Sanz4 and Mónica Vázquez4, 1Hospital Ramon y Cajal, Madrid, Madrid, Spain, 2PRINTO, Istituto Giannina Gaslini, Genova, Italy, 3Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, 4Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain

    Background/Purpose: To determine the association between the occurrence of uveitis flares in patients with Juvenile Idiopathic Arthritis (JIA) and the de-intensification of immunosuppressive treatment.Methods: We…
  • « Previous Page
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology